News articles about Lexicon Pharmaceuticals (NASDAQ:LXRX) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.8931041315693 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Lexicon Pharma (LXRX) Announces EMA Acceptance of MAA for Sotagliflozin to Treat Adults With Type 1 Diabetes (streetinsider.com)
- Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults With Type 1 Diabetes (finance.yahoo.com)
- Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes (feeds.benzinga.com)
- Blog Exposure – Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes (finance.yahoo.com)
- Lexicon Pharma (LXRX) Submits NDA to FDA for Sotagliflozin to Treat Adults With Type 1 Diabetes (streetinsider.com)
A number of research firms have issued reports on LXRX. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, March 21st. BidaskClub raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 23rd. Needham & Company LLC downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. ValuEngine downgraded Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, JPMorgan Chase downgraded Lexicon Pharmaceuticals from a “neutral” rating to an “underweight” rating and lowered their price target for the company from $15.00 to $10.00 in a research report on Wednesday, February 14th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $24.00.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 143.31% and a negative net margin of 142.86%. The firm had revenue of $33.05 million during the quarter, compared to the consensus estimate of $29.84 million. During the same quarter in the previous year, the business earned ($0.31) earnings per share. The firm’s quarterly revenue was up 43.7% compared to the same quarter last year. research analysts anticipate that Lexicon Pharmaceuticals will post -1.39 earnings per share for the current year.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.